
    
      This is a multicenter, Phase 2 study of enzastaurin and sunitinib versus placebo and
      sunitinib as first-line therapy in participants with metastatic renal cell carcinoma,
      containing 2 parts. Part 1 is a safety lead-in study with 12 participants and possible dose
      escalation. Part 2 is a randomized, double-blind, Phase 2 study in 110 participants.
    
  